Mendus AB (publ) Asset Resilience Ratio
Mendus AB (publ) asset resilience ratio. Mendus AB (publ) (IMMU) has an Asset Resilience Ratio of 10.29% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Mendus AB (publ) (IMMU) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Mendus AB (publ) (2014–2025)
Asset resilience ratio of Mendus AB (publ) from 2014 to 2025. This chart shows how Mendus AB (publ)'s Asset Resilience Ratio has changed over time. Read total liabilities of Mendus AB (publ) for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Mendus AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see IMMU total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr64.66 Million | 10.29% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr64.66 Million | 10.29% |
Asset Resilience Insights
- Moderate Liquidity: Mendus AB (publ) has 10.29% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Mendus AB (publ) Industry Peers by Asset Resilience Ratio
Compare Mendus AB (publ)'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Mendus AB (publ) Asset Resilience Ratio by Year (2014–2025)
Mendus AB (publ) asset resilience ratio by year from 2014 to 2025. The table below shows the annual Asset Resilience Ratio data for Mendus AB (publ).
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 10.29% | Skr64.66 Million ≈ $6.96 Million |
Skr628.32 Million ≈ $67.62 Million |
-4.34pp |
| 2024-12-31 | 14.63% | Skr101.91 Million ≈ $10.97 Million |
Skr696.36 Million ≈ $74.94 Million |
-1.34pp |
| 2023-12-31 | 15.98% | Skr120.78 Million ≈ $13.00 Million |
Skr755.95 Million ≈ $81.35 Million |
+9.23pp |
| 2022-12-31 | 6.75% | Skr41.85 Million ≈ $4.50 Million |
Skr620.39 Million ≈ $66.76 Million |
-14.80pp |
| 2021-12-31 | 21.54% | Skr155.31 Million ≈ $16.71 Million |
Skr720.98 Million ≈ $77.59 Million |
-1.47pp |
| 2020-12-31 | 23.01% | Skr167.64 Million ≈ $18.04 Million |
Skr728.66 Million ≈ $78.42 Million |
+18.53pp |
| 2019-12-31 | 4.47% | Skr13.59 Million ≈ $1.46 Million |
Skr303.83 Million ≈ $32.70 Million |
-94.27pp |
| 2018-12-31 | 98.74% | Skr444.70 Million ≈ $47.86 Million |
Skr450.37 Million ≈ $48.47 Million |
+46.61pp |
| 2017-12-31 | 52.13% | Skr128.32 Million ≈ $13.81 Million |
Skr246.15 Million ≈ $26.49 Million |
+44.29pp |
| 2016-12-31 | 7.84% | Skr9.53 Million ≈ $1.03 Million |
Skr121.57 Million ≈ $13.08 Million |
+1.68pp |
| 2015-12-31 | 6.15% | Skr9.49 Million ≈ $1.02 Million |
Skr154.24 Million ≈ $16.60 Million |
-43.72pp |
| 2014-12-31 | 49.87% | Skr35.43 Million ≈ $3.81 Million |
Skr71.03 Million ≈ $7.64 Million |
-- |
About Mendus AB (publ)
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of tumor recurrence and established tumors. Its lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase II CADENCE clinical trial to treat AML; and Phase I ALISON clinical trial for the treatment of ovarian cancers. The com… Read more